These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 25015764)
21. CDH13 promoter region is specifically methylated in poorly differentiated colorectal cancer. Hibi K; Nakayama H; Kodera Y; Ito K; Akiyama S; Nakao A Br J Cancer; 2004 Mar; 90(5):1030-3. PubMed ID: 14997203 [TBL] [Abstract][Full Text] [Related]
22. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617 [TBL] [Abstract][Full Text] [Related]
23. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma. Kim JS; Han J; Shim YM; Park J; Kim DH Cancer; 2005 Nov; 104(9):1825-33. PubMed ID: 16177988 [TBL] [Abstract][Full Text] [Related]
24. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer. Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819 [TBL] [Abstract][Full Text] [Related]
25. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579 [TBL] [Abstract][Full Text] [Related]
26. Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Sathyanarayana UG; Padar A; Suzuki M; Maruyama R; Shigematsu H; Hsieh JT; Frenkel EP; Gazdar AF Clin Cancer Res; 2003 Dec; 9(17):6395-400. PubMed ID: 14695140 [TBL] [Abstract][Full Text] [Related]
27. MT1G hypermethylation is associated with higher tumor stage in prostate cancer. Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685 [TBL] [Abstract][Full Text] [Related]
28. Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer. Zhong YH; Peng H; Cheng HZ; Wang P Asian Pac J Cancer Prev; 2015; 16(3):1139-43. PubMed ID: 25735345 [TBL] [Abstract][Full Text] [Related]
29. Correlation between methylation of the E-Cadherin gene and malignancy of prostate cancer. Zhang SQ; Zhang GQ; Zhang L Genet Mol Res; 2016 Jul; 15(2):. PubMed ID: 27420993 [TBL] [Abstract][Full Text] [Related]
30. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa. Roman-Gomez J; Castillejo JA; Jimenez A; Cervantes F; Boque C; Hermosin L; Leon A; Grañena A; Colomer D; Heiniger A; Torres A J Clin Oncol; 2003 Apr; 21(8):1472-9. PubMed ID: 12697869 [TBL] [Abstract][Full Text] [Related]
31. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374 [TBL] [Abstract][Full Text] [Related]
32. Clinical and prognostic effects of Xia L; Zhang W; Gao L Biomarkers; 2019 Nov; 24(7):700-711. PubMed ID: 31382782 [No Abstract] [Full Text] [Related]
33. Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. Sun D; Zhang Z; Van do N; Huang G; Ernberg I; Hu L Oral Oncol; 2007 Jan; 43(1):82-7. PubMed ID: 16807071 [TBL] [Abstract][Full Text] [Related]
34. [Detection of free tumor-related DNA in the serum of breast cancer patients]. Zhang JJ; Ouyang T; Wan WH; Deng GR Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):609-13. PubMed ID: 18210882 [TBL] [Abstract][Full Text] [Related]
35. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291 [TBL] [Abstract][Full Text] [Related]
36. [Methylation status of JunB and CDH13 gene promoter in CD34(+)CD38(-) chronic myelogenous leukemia cells]. Wang XJ; Li J; Fu BJ; Guo LL; Zhang JH; Huang SA Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1405-8. PubMed ID: 20030915 [TBL] [Abstract][Full Text] [Related]
37. DNA methylation markers and early recurrence in stage I lung cancer. Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602 [TBL] [Abstract][Full Text] [Related]
38. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Chang HW; Chow V; Lam KY; Wei WI; Yuen A Cancer; 2002 Jan; 94(2):386-92. PubMed ID: 11900224 [TBL] [Abstract][Full Text] [Related]
39. Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma. Wang XB; Lin YL; Li ZG; Ma JH; Li J; Ma JG J Int Med Res; 2014 Apr; 42(2):292-9. PubMed ID: 24567353 [TBL] [Abstract][Full Text] [Related]
40. CDH13 and FLBN3 gene methylation are associated with poor prognosis in colorectal cancer. Wang Z; Yuan X; Jiao N; Zhu H; Zhang Y; Tong J Pathol Oncol Res; 2012 Apr; 18(2):263-70. PubMed ID: 21796503 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]